Protalix BioTherapeutics, Inc.
PLX
$1.68
$0.010.30%
AMEX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 156.15% | 142.70% | -42.93% | -64.73% | -190.49% |
| Total Depreciation and Amortization | 10.05% | 8.74% | 7.70% | 9.49% | 11.27% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -79.23% |
| Total Other Non-Cash Items | -44.92% | 35.66% | 610.82% | 760.66% | 388.36% |
| Change in Net Operating Assets | -260.59% | -281.48% | -419.85% | 107.70% | 166.80% |
| Cash from Operations | -221.19% | 19.15% | -109.75% | 758.12% | 210.02% |
| Capital Expenditure | -49.95% | 14.86% | 33.96% | -11.58% | 0.45% |
| Sale of Property, Plant, and Equipment | -100.00% | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -173.46% | 126.79% | 126.77% | 135.34% | 297.04% |
| Cash from Investing | -186.33% | 119.34% | 120.48% | 125.26% | 268.18% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 100.00% | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -16.59% | -85.30% | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 162.71% | -- | -212.32% | -168.09% | -171.05% |
| Foreign Exchange rate Adjustments | 167.86% | 176.19% | 130.38% | 121.93% | 50.44% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -296.57% | 77.79% | -33.02% | -159.39% | -27.74% |